Are there Negative CNS Impacts of Aluminum Adjuvants Used in Vaccines and Immunotherapy?

References

• Baylor NW, Egan W, Richman P. Aluminum salts in vaccines – US perspective. Vaccine 20(Suppl. 3), S18–S23 (2002).
   PubMed Web of Science ®Google Scholar
• Glenny AT, Pope CG, Waddington H, Wallace U. XXIII – the antigenic value of toxoid precipitated by potassium alum. J. Pathol Bacteriol. 29, 38–39 (1926).
   Google Scholar
• Exley C. Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy. Allergy Asthma Clin. Immunol. 10(1), 4 (2014).
   PubMedGoogle Scholar
• Shaw CA, Petrik MS. Aluminum hydroxide injections lead to motor deficits and motor neuron degeneration. J. Inorg. Biochem. 103(11), 1555–1562 (2009).
   PubMed Web of Science ®Google Scholar
• Li X, Zheng H, Zhang Z et al. Glia activation induced by peripheral administration of aluminum oxide nanoparticles in rat brains. Nanomedicine 5(4), 473–479 (2009).
   PubMed Web of Science ®Google Scholar
• Passeri E, Villa C, Couette M et al. Long-term follow-up of cognitive dysfunction in patients with aluminum hydroxide-induced macrophagic myofasciitis (MMF). J. Inorg. Biochem. 105(11), 1457–1463 (2011).
   PubMed Web of Science ®Google Scholar
• Couette M, Boisse MF, Maison P et al. Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction. J. Inorg. Biochem. 103(11), 1571–1578 (2009).
   PubMed Web of Science ®Google Scholar
• Gherardi R, Authier F. Macrophagic myofasciitis: characterization and pathophysiology. Lupus 21(2), 184–189 (2012).
   PubMed Web of Science ®Google Scholar
• Zafrir Y, Agmon-Levin N, Paz Z, Shilton T, Shoenfeld Y. Autoimmunity following Hepatitis B vaccine as part of the spectrum of ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’ (ASIA): analysis of 93 cases. Lupus 21(2), 146–152 (2012).
   PubMed Web of Science ®Google Scholar
• Shaw AC, Li Y, Tomljenovic L. Administration of aluminium in vaccine-relevant amounts in neonatal mice is associated with long-term adverse neurological outcomes. J. Inorg. Biochem. 128, 237–244 (2013).
   PubMed Web of Science ®Google Scholar
• Khan Z, Combadiere C, Authier FJ et al. Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. BMC Med. 11, 99 (2013).
   PubMed Web of Science ®Google Scholar
• Offit PA, Jew RK. Addressing parents’ concerns: do vaccines contain harmful preservatives, adjuvants, additives, or residuals? Pediatrics 112(6 Pt 1), 1394–1397 (2003).
   PubMed Web of Science ®Google Scholar
• Eldred BE, Dean AJ, McGuire TM, Nash AL. Vaccine components and constituents: responding to consumer concerns. Med. J. Aust. 184(4), 170–175 (2006).
   PubMed Web of Science ®Google Scholar
• Priest ND. Satellite symposium on Alzheimer’s disease and dietary aluminium. Proc. Nutr. Soc. 52, 231–240 (1993).
   PubMed Web of Science ®Google Scholar
• Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for aluminum. US Department of Health and Human services, Atlanta, GA, USA (2008). www.atsdr.cdc.gov/toxprofiles/tp22.pdf
   Google Scholar
• Exley C. Human exposure to aluminium. Environ. Sci. Process Impacts 15(10), 1807–1816 (2013).
   PubMed Web of Science ®Google Scholar
• Tomljenovic L. Aluminum and Alzheimer’s disease: after a century of controversy, is there a plausible link? J. Alzheimers Dis. 23(4), 567–598 (2011).
   PubMed Web of Science ®Google Scholar
• Walton JR. Evidence that Ingested Aluminum additives contained in processed foods and alum-treated drinking water are a major risk factor for Alzheimer’s Disease. Curr. Inorg. Chem. 2(1), 19–39 (2012).
   Google Scholar
• Exley C, House E. Aluminium in the human brain. Monatsh. Chem. 142, 357–363 (2011).
   Web of Science ®Google Scholar
• Fewtrell MS, Edmonds CJ, Isaacs E, Bishop NJ, Lucas A. Aluminium exposure from parenteral nutrition in preterm infants and later health outcomes during childhood and adolescence. Proc. Nutr. Soc. 70(3), 299–304 (2011).
   PubMed Web of Science ®Google Scholar
• Power G, Loh JSC, Vernon C. Organic compounds in the processing of lateritic bauxites to alumina Part 2: effects of organics in the Bayer process. Hydrometallurgy 127–128, 125–149 (2012).
   Web of Science ®Google Scholar
• Dapson RW. The history, chemistry and modes of action of carmine and related dyes. Biotech. Histochem. 82(4), 173–187 (2007).
   PubMed Web of Science ®Google Scholar
• Nicholson S, Exley C. Aluminum: a potential pro-oxidant in sunscreens/sunblocks? Free Radic. Biol. Med. 43(8), 1216–1217 (2007).
   PubMed Web of Science ®Google Scholar
• Ai-Ashmawy MA. Prevalence and public health significance of aluminum residues in milk and some dairy products. J. Food Sci. 76(3), T73–T76 (2011).
   PubMed Web of Science ®Google Scholar
• Bishop NJ, Morley R, Day JP, Lucas A. Aluminum neurotoxicity in preterm infants receiving intravenous-feeding solutions. N. Engl. J. Med. 336(22), 1557–1561 (1997).
   PubMed Web of Science ®Google Scholar
• Fewtrell MS, Bishop NJ, Edmonds CJ, Isaacs EB, Lucas A. Aluminum exposure from parenteral nutrition in preterm infants: bone health at 15-year follow-up. Pediatrics 124(5), 1372–1379 (2009).
   PubMed Web of Science ®Google Scholar
• Gies WJ. Some objections to the use of alum baking-powder. JAMA 57(10), 816–821 (1911).
   Google Scholar
• Exley C. Aluminium and medicine. In: Molecular and Supramolecular Bioinorganic Chemistry: Applications in Medical Sciences. Merce ALR, Felcman J, Recio MAL (Eds). Nova Biomedical Books, NY, USA, 45–68 (2009).
   Google Scholar
• Tomljenovic L, Shaw CA. Aluminum vaccine adjuvants: are they safe? Curr. Med. Chem. 18(17), 2630–2637 (2011).
   PubMed Web of Science ®Google Scholar
• Yokel RA, Hicks CL, Florence RL. Aluminum bioavailability from basic sodium aluminum phosphate, an approved food additive emulsifying agent, incorporated in cheese. Food Chem. Toxicol. 46(6), 2261–2266 (2008).
   PubMed Web of Science ®Google Scholar
• Yokel RA, McNamara PJ. Aluminium toxicokinetics: an updated minireview. Pharmacol. Toxicol. 88(4), 159–167 (2001).
   PubMedGoogle Scholar
• Walton JR. Brain lesions comprised of aluminum-rich cells that lack microtubules may be associated with the cognitive deficit of Alzheimer’s disease. Neurotoxicology 30(6), 1059–1069 (2009).
   PubMed Web of Science ®Google Scholar
• Walton JR. Aluminum in hippocampal neurons from humans with Alzheimer’s disease. Neurotoxicology 27(3), 385–394 (2006).
   PubMed Web of Science ®Google Scholar
• Kowall NW, Pendlebury WW, Kessler JB, Perl DP, Beal MF. Aluminum-induced neurofibrillary degeneration affects a subset of neurons in rabbit cerebral cortex, basal forebrain and upper brainstem. Neuroscience 29(2), 329–337 (1989).
   PubMed Web of Science ®Google Scholar
• Polizzi S, Pira E, Ferrara M et al. Neurotoxic effects of aluminium among foundry workers and Alzheimer’s disease. Neurotoxicology 23(6), 761–774 (2002).
   PubMed Web of Science ®Google Scholar
• Sinczuk-Walczak H, Szymczak M, Razniewska G, Matczak W, Szymczak W. Effects of occupational exposure to aluminum on nervous system: clinical and electroencephalographic findings. Int. J. Occup. Med. Environ. Health 16(4), 301–310 (2003).
   PubMedGoogle Scholar
• Saiyed SM, Yokel RA. Aluminium content of some foods and food products in the USA, with aluminium food additives. Food Addit. Contam. 22(3), 234–244 (2005).
   PubMed Web of Science ®Google Scholar
• Greger JL. Aluminum metabolism. Annu Rev. Nutr. 13, 43–63 (1993).
   PubMed Web of Science ®Google Scholar
• Pennington JA, Schoen SA. Estimates of dietary exposure to aluminium. Food Addit. Contam. 12(1), 119–128 (1995).
   PubMed Web of Science ®Google Scholar
• Food and Agriculture Organization (FAO)/WHO. Summary and conclusions of the sixty-seventh meeting of the Joint FAO/WHO Expert Committee on Food Additives (JECFA), 67th meeting in Rome, Italy, 20–29 June 2006. ftp://ftp.fao.org/ag/agn/jecfa/jecfa67_final.pdf
   Google Scholar
• Flendrig JA, Kruis H, Das HA. Aluminium intoxication: the cause of dialysis dementia? Proc. Eur. Dial. Transpl. Assoc. 13, 355–368 (1976).
   Google Scholar
• Rozas VV, Port FK, Easterling RE. An outbreak of dialysis dementia due to aluminum in the dialysate. J. Dial. 2(5–6), 459–470 (1978).
   PubMed Web of Science ®Google Scholar
• Melendez L, Santos D, Luna Polido L et al. Aluminium and other metals may pose a risk to children with autism spectrum disorder: biochemical and behavioural impairments. Clin. Exp. Pharmacol. 3, 1 (2013).
   Google Scholar
• Yasuda H, Tsutsui T. Assessment of infantile mineral imbalances in autism spectrum disorders (ASDs). Int. J. Environ. Res. Public Health 10(11), 6027–6043 (2013).
   PubMed Web of Science ®Google Scholar
• Seneff S, Davidson RM, Liu J. Empirical data confirm autism symptoms related to aluminum and acetaminophen exposure. Entropy 14, 2227–2253 (2012).
   Web of Science ®Google Scholar
• Tomljenovic L, Shaw CA. Do aluminum vaccine adjuvants contribute to the rising prevalence of autism? J. Inorg. Biochem. 105(11), 1489–1499 (2011).
   PubMed Web of Science ®Google Scholar
• Perl DP, Moalem S. Aluminum, Alzheimer’s disease and the geospatial occurrence of similar disorders. Rev. Mineral Geochem. 64, 115–134 (2006).
   Web of Science ®Google Scholar
• Exley C. Aluminum and Alzheimer’s disease. J. Alzheimers Dis. 3(6), 551–552 (2001).
   PubMed Web of Science ®Google Scholar
• McLachlan DRC, Krishnan SS, Dalton AJ. Brain aluminum distribution in Alzheimer’s disease and experimental neurofibrillary degeneration. Science 180(85), 511–513 (1973).
   PubMedGoogle Scholar
• McLachlan DRC, Dalton AJ. Alterations in short-term retention, conditioned avoidance response acquisition and motivation following aluminum induced neurofibrillary degeneration. Physiol. Behav. 10(5), 925–933 (1973).
   PubMed Web of Science ®Google Scholar
• Lukiw WJ. Aluminum and gene transcription in the mammalian central nervous system – implications for Alzheimer’s disease. In: Aluminium and Alzheimer’s Disease: The science that Describes the Link (1st Edition). Exley C (Ed.), Elsevier Science, Amsterdam, The Netherlands, 147–169 (2001).
   Google Scholar
• Lukiw WJ. Evidence supporting a biological role for aluminum in chromatin compaction and epigenetics. J. Inorg. Biochem. 104(9), 1010–1012 (2010).
   PubMed Web of Science ®Google Scholar
• Lukiw WJ, Kruck TP, McLachlan DR. Linker histone–DNA complexes: enhanced stability in the presence of aluminum lactate and implications for Alzheimer’s disease. FEBS Lett. 253(1–2), 59–62 (1989).
   PubMed Web of Science ®Google Scholar
• Wu J, Du F, Zhang P, Khan IA, Chen J, Liang Y. Thermodynamics of the interaction of aluminum ions with DNA: implications for the biological function of aluminum. J. Inorg. Biochem. 99(5), 1145–1154 (2005).
   PubMed Web of Science ®Google Scholar
• Lukiw WJ, LeBlanc HJ, Carver LA, McLachlan DR, Bazan NG. Run-on gene transcription in human neocortical nuclei. Inhibition by nanomolar aluminum and implications for neurodegenerative disease. J. Mol. Neurosci. 11(1), 67–78 (1998).
   PubMed Web of Science ®Google Scholar
• McLachlan DRC, Lukiw WJ, Kruck TPA. Aluminum, altered transcription, and the pathogenesis of Alzheimer’s disease. Environ. Geochem. Health 12(1–2), 103–114 (1990).
   PubMed Web of Science ®Google Scholar
• Alexandrov PN, Zhao Y, Pogue AI et al. Synergistic effects of iron and aluminum on stress-related gene expression in primary human neural cells. J. Alzheimers Dis. 8(2), 117–127 ; discussion 209–115 (2005).
   PubMed Web of Science ®Google Scholar
• Lukiw WJ, Percy ME, Kruck TP. Nanomolar aluminum induces pro-inflammatory and pro-apoptotic gene expression in human brain cells in primary culture. J. Inorg. Biochem. 99(9), 1895–1898 (2005).
   PubMed Web of Science ®Google Scholar
• Lukiw WJ, Bazan NG. Neuroinflammatory signaling upregulation in Alzheimer’s disease. Neurochem. Res. 25(9–10), 1173–1184 (2000).
   PubMed Web of Science ®Google Scholar
• Herbert MR, Russo JP, Yang S et al. Autism and environmental genomics. Neurotoxicology 27(5), 671–684 (2006).
   PubMedGoogle Scholar
• Ruiperez F, Mujika JI, Ugalde JM, Exley C, Lopez X. Pro-oxidant activity of aluminum: promoting the Fenton reaction by reducing Fe(III) to Fe(II). J. Inorg. Biochem. 117, 118–123 (2012).
   PubMed Web of Science ®Google Scholar
• Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl Acad. Sci. USA 94(18), 9866–9868 (1997).
   PubMed Web of Science ®Google Scholar
• Carson BL. Aluminum compounds. Review of toxicological literature, abridged final report: p 84. Integrated Laboratory Systems, Research Triangle Park, NC, USA (2000). http://ntp.niehs.nih.gov/ntp/htdocs/chem_background/exsumpdf/aluminum_508.pdf
   Google Scholar
• Shafer TJ, Mundy WR. Effects of aluminum on neuronal signal transduction: mechanisms underlying disruption of phosphoinositide hydrolysis. Gen. Pharmacol. 26(5), 889–895 (1995).
   PubMedGoogle Scholar
• Mundy WR, Kodavanti PR, Dulchinos VF, Tilson HA. Aluminum alters calcium transport in plasma membrane and endoplasmic reticulum from rat brain. J. Biochem. Toxicol. 9(1), 17–23 (1994).
   PubMedGoogle Scholar
• Macdonald TL, Humphreys WG, Martin RB. Promotion of tubulin assembly by aluminum ion in vitro. Science 236(4798), 183–186 (1987).
   PubMed Web of Science ®Google Scholar
• McLachlan DRC, Farnell BJ. Cellular mechanisms of aluminium toxicity. Ann. Ist. Super Sanita 22(2), 697–702 (1986).
   PubMedGoogle Scholar
• Siegel N, Haug A. Aluminum interaction with calmodulin. Evidence for altered structure and function from optical and enzymatic studies. Biochim. Biophys. Acta 744(1), 36–45 (1983).
   PubMedGoogle Scholar
• Joshi JG. Neurochemical hypothesis: participation by aluminum in producing critical mass of colocalized errors in brain leads to neurological disease. Comp. Biochem. Physiol. C. 100(1–2), 103–105 (1991).
   PubMed Web of Science ®Google Scholar
• Joshi JG, Dhar M, Clauberg M, Chauthaiwale V. Iron and aluminum homeostasis in neural disorders. Environ. Health Perspect. 102(Suppl. 3), 207–213 (1994).
   PubMedGoogle Scholar
• Roskams AJ, Connor JR. Aluminum access to the brain: a role for transferrin and its receptor. Proc. Natl Acad. Sci. USA 87(22), 9024–9027 (1990).
   PubMed Web of Science ®Google Scholar
• Exley C. A molecular mechanism of aluminium-induced Alzheimer’s disease? J. Inorg. Biochem. 76(2), 133–140 (1999).
   PubMed Web of Science ®Google Scholar
• Silva VS, Duarte AI, Rego AC, Oliveira CR, Goncalves PP. Effect of chronic exposure to aluminium on isoform expression and activity of rat (Na+/K+)ATPase. Toxicol. Sci. 88(2), 485–494 (2005).
   PubMed Web of Science ®Google Scholar
• Exley C, Price NC, Birchall JD. Aluminum inhibition of hexokinase activity in vitro: a study in biological availability. J. Inorg. Biochem. 54(4), 297–304 (1994).
   PubMed Web of Science ®Google Scholar
• McLachlan DRC, Dam TV, Farnell BJ, Lewis PN. Aluminum inhibition of ADP-ribosylation in vivo and in vitro. Neurobehav. Toxicol. Teratol. 5(6), 645–647 (1983).
   PubMedGoogle Scholar
• Cherroret G, Desor D, Hutin MF, Burnel D, Capolaghi B, Lehr PR. Effects of aluminum chloride on normal and uremic adult male rats. Tissue distribution, brain choline acetyltransferase activity, and some biological variables. Biol. Trace Elem. Res. 54(1), 43–53 (1996).
   PubMed Web of Science ®Google Scholar
• King RG. Do raised brain aluminium levels in Alzheimer’s dementia contribute to cholinergic neuronal deficits? Med. Hypotheses 14(3), 301–306 (1984).
   PubMed Web of Science ®Google Scholar
• King RG, Sharp JA, Boura AL. Aluminium, choline transportation and Alzheimer’s disease. Med. J. Aust. 2(12), 606–607 (1983).
   PubMed Web of Science ®Google Scholar
• Huber CT, Frieden E. The inhibition of ferroxidase by trivalent and other metal ions. J. Biol. Chem. 245(15), 3979–3984 (1970).
   PubMed Web of Science ®Google Scholar
• Abdel-Ghany M, el-Sebae AK, Shalloway D. Aluminum-induced nonenzymatic phospho-incorporation into human tau and other proteins. J. Biol. Chem. 268(16), 11976–11981 (1993).
   PubMed Web of Science ®Google Scholar
• Banks WA, Kastin AJ. Aluminum-induced neurotoxicity: alterations in membrane function at the blood–brain barrier. Neurosci. Biobehav. Rev. 13(1), 47–53 (1989).
   PubMed Web of Science ®Google Scholar
• Walton JR. Functional impairment in aged rats chronically exposed to human range dietary aluminum equivalents. Neurotoxicology 30(2), 182–193 (2009).
   PubMed Web of Science ®Google Scholar
• Walton JR, Wang MX. APP expression, distribution and accumulation are altered by aluminum in a rodent model for Alzheimer’s disease. J. Inorg. Biochem. 103(11), 1548–1554 (2009).
   PubMed Web of Science ®Google Scholar
• Nehru B, Anand P. Oxidative damage following chronic aluminium exposure in adult and pup rat brains. J. Trace Elem. Med. Biol. 19(2–3), 203–208 (2005).
   PubMed Web of Science ®Google Scholar
• Jing Y, Wang Z, Song Y. Quantitative study of aluminum-induced changes in synaptic ultrastructure in rats. Synapse 52(4), 292–298 (2004).
   PubMed Web of Science ®Google Scholar
• Deloncle R, Fauconneau B, Piriou A, Huguet F, Guillard O. Aluminum L-glutamate complex in rat brain cortex: in vivo prevention of aluminum deposit by magnesium D-aspartate. Brain Res. 946(2), 247–252 (2002).
   PubMed Web of Science ®Google Scholar
• Matyja E. Aluminum enhances glutamate-mediated neurotoxicity in organotypic cultures of rat hippocampus. Folia Neuropathol. 38(2), 47–53 (2000).
   PubMed Web of Science ®Google Scholar
• Walton JR. Amyloid, aluminium and the aetiology of Alzheimer’s disease. Med. J. Aust. 164(6), 382–383 (1996).
   PubMedGoogle Scholar
• Bondy SC, Ali SF, Guo-Ross S. Aluminum but not iron treatment induces pro-oxidant events in the rat brain. Mol. Chem. Neuropathol. 34(2–3), 219–232 (1998).
   PubMedGoogle Scholar
• Jope RS, Johnson GV. Neurotoxic effects of dietary aluminium. Ciba Found Symp. 169, 254–262 ; discussion 262–257 (1992).
   PubMedGoogle Scholar
• Johnson GV, Watson AL Jr, Lartius R, Uemura E, Jope RS. Dietary aluminum selectively decreases MAP-2 in brains of developing and adult rats. Neurotoxicology 13(2), 463–474 (1992).
   PubMed Web of Science ®Google Scholar
• Bowdler NC, Beasley DS, Fritze EC et al. Behavioral effects of aluminum ingestion on animal and human subjects. Pharmacol. Biochem. Behav. 10(4), 505–512 (1979).
   PubMed Web of Science ®Google Scholar
• Thorne BM, Donohoe T, Lin KN, Lyon S, Medeiros DM, Weaver ML. Aluminum ingestion and behavior in the Long-Evans rat. Physiol. Behav. 36(1), 63–67 (1986).
   PubMed Web of Science ®Google Scholar
• Yokel RA, Allen DD, Meyer JJ. Studies of aluminum neurobehavioral toxicity in the intact mammal. Cell Mol. Neurobiol. 14(6), 791–808 (1994).
   PubMed Web of Science ®Google Scholar
• Campbell A, Becaria A, Lahiri DK, Sharman K, Bondy SC. Chronic exposure to aluminum in drinking water increases inflammatory parameters selectively in the brain. J. Neurosci. Res. 75(4), 565–572 (2004).
   PubMed Web of Science ®Google Scholar
• Pivnick EK, Kerr NC, Kaufman RA, Jones DP, Chesney RW. Rickets secondary to phosphate depletion. A sequela of antacid use in infancy. Clin. Pediatr. 34(2), 73–78 (1995).
   PubMed Web of Science ®Google Scholar
• McDermott JR, Smith AI, Iqbal K, Wisniewski HM. Brain aluminum in aging and Alzheimer disease. Neurology 29(6), 809–814 (1979).
   PubMed Web of Science ®Google Scholar
• Crapper DR, Quittkat S, Krishnan SS, Dalton AJ, De Boni U. Intranuclear aluminum content in Alzheimer’s disease, dialysis encephalopathy, and experimental aluminum encephalopathy. Acta Neuropathol. 50(1), 19–24 (1980).
   PubMed Web of Science ®Google Scholar
• Perl DP, Brody AR. Alzheimer’s disease: x-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science 208(4441), 297–299 (1980).
   PubMed Web of Science ®Google Scholar
• Candy JM, Oakley AE, Mountfort SA et al. The imaging and quantification of aluminium in the human brain using dynamic secondary ion mass spectrometry (SIMS). Biol. Cell 74(1), 109–118 (1992).
   PubMed Web of Science ®Google Scholar
• Edwardson JA, Candy JM, Ince PG et al. Aluminium accumulation, beta-amyloid deposition and neurofibrillary changes in the central nervous system. Ciba Found Symp. 169, 165–179 ; discussion 179–185 (1992).
   PubMedGoogle Scholar
• Lukiw WJ, Krishnan B, Wong L, Kruck TP, Bergeron C, Crapper McLachlan DR. Nuclear compartmentalization of aluminum in Alzheimer’s disease (AD). Neurobiol. Aging. 13(1), 115–121 (1992).
   PubMed Web of Science ®Google Scholar
• Perl DP, Moalem S. Aluminum and Alzheimer’s disease, a personal perspective after 25 years. J. Alzheimers Dis. 9(3 Suppl.), 291–300 (2006).
   PubMedGoogle Scholar
• International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431(7011), 931–945 (2004).
   PubMed Web of Science ®Google Scholar
• Bohrer D, do Nascimento PC, Mendonca JK, Polli VG, de Carvalho LM. Interaction of aluminium ions with some amino acids present in human blood. Amino Acids 27(1), 75–83 (2004).
   PubMed Web of Science ®Google Scholar
• Brothers PJ, Ruggerio CE. Coordination and solution chemistry of the metals: biological, medical, and environmental relevance. In: The Group 13 Metals Aluminium, Gallium, Indium and Thallium, Chemical Patterns and Peculiarities. Aldridge S, Downs AJ (Eds.), John Wiley and Sons, Chichester, UK, 519–611 (2011).
   Google Scholar
• Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity in pediatric populations. Lupus 21(2), 223–230 (2012).
   PubMed Web of Science ®Google Scholar
• Caulfield MJ, Shi L, Wang S et al. Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice. Hum. Vaccin. 3(4), 139–145 (2007).
   PubMed Web of Science ®Google Scholar
• Mitkus RJ, King DB, Hess MA, Forshee RA, Walderhaug MO. Updated aluminum pharmacokinetics following infant exposures through diet and vaccination. Vaccine 29(51), 9538–9543 (2011).
   PubMed Web of Science ®Google Scholar
• Priest ND. The biological behaviour and bioavailability of aluminium in man, with special reference to studies employing aluminium-26 as a tracer: review and study update. J. Environ. Monit. 6(5), 375–403 (2004).
   PubMedGoogle Scholar
• Flarend RE, Hem SL, White JL et al. In vivo absorption of aluminium-containing vaccine adjuvants using 26Al. Vaccine 15(12–13), 1314–1318 (1997).
   PubMed Web of Science ®Google Scholar
• Hem SL. Elimination of aluminum adjuvants. Vaccine 20(Suppl.), S40–S43 (2002).
   PubMedGoogle Scholar
• Lee SH. Melting profiles may affect detection of residual HPV L1 gene DNA fragments in Gardasil. Curr. Med. Chem. 21(7), 932–940 (2014).
   PubMed Web of Science ®Google Scholar
• Lee SH. Topological conformational changes of human papillomavirus (HPV) DNA bound to an insoluble aluminum salt-A study by low temperature PCR Adv. Biol. Chem. 3, 76–85 (2013).
   Google Scholar
• Lee SH. Detection of human papillomavirus L1 gene DNA fragments in postmortem blood and spleen after Gardasil® vaccination – a case report Adv. Biosc. Biotech. 3, 1214–1224 (2012).
   Google Scholar
• Walton JR. A longitudinal study of rats chronically exposed to aluminum at human dietary levels. Neurosci. Lett. 412(1), 29–33 (2007).
   PubMed Web of Science ®Google Scholar
• Gherardi RK, Coquet M, Cherin P et al. Macrophagic myofasciitis: an emerging entity. Groupe d’Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l’Association Francaise contre les Myopathies (AFM). Lancet 352(9125), 347–352 (1998).
   PubMed Web of Science ®Google Scholar
• Gherardi RK, Coquet M, Cherin P et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 124(Pt 9), 1821–1831 (2001).
   PubMedGoogle Scholar
• Authier FJ, Sauvat S, Champey J, Drogou I, Coquet M, Gherardi RK. Chronic fatigue syndrome in patients with macrophagic myofasciitis. Arthritis Rheum. 48(2), 569–570 (2003).
   PubMedGoogle Scholar
• Gherardi RK, Authier FJ. Aluminum inclusion macrophagic myofasciitis: a recently identified condition. Immunol. Allergy Clin. North Am. 23(4), 699–712 (2003).
   PubMed Web of Science ®Google Scholar
• Hassan IS, Bannister BA, Akbar A, Weir W, Bofill M. A study of the immunology of the chronic fatigue syndrome: correlation of immunologic parameters to health dysfunction. Clin. Immunol. Immunopathol. 87(1), 60–67 (1998).
   PubMedGoogle Scholar
• Landay AL, Jessop C, Lennette ET, Levy JA. Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet 338(8769), 707–712 (1991).
   PubMed Web of Science ®Google Scholar
• Konstantinov K, von Mikecz A, Buchwald D, Jones J, Gerace L, Tan EM. Autoantibodies to nuclear envelope antigens in chronic fatigue syndrome. J. Clin. Invest. 98(8), 1888–1896 (1996).
   PubMed Web of Science ®Google Scholar
• Nishikai M, Tomomatsu S, Hankins RW et al. Autoantibodies to a 68/48 kDa protein in chronic fatigue syndrome and primary fibromyalgia: a possible marker for hypersomnia and cognitive disorders. Rheumatology 40(7), 806–810 (2001).
   PubMed Web of Science ®Google Scholar
• Gherardi RK, Plonquet A, André C, Intrator L, Poron F, Coquet M. Macrophagic myofasciitis: evidence for chronic local and systemic immune activation associated with persistence of aluminum hydroxide-loaded macrophages in muscle [abstract]. Neurology 56(Suppl. 3), A62 (2001).
   PubMedGoogle Scholar
• Brewer JM. (How) do aluminium adjuvants work? Immunol. Lett. 102(1), 10–15 (2006).
   PubMed Web of Science ®Google Scholar
• Gherardi RK. [Lessons from macrophagic myofasciitis: towards definition of a vaccine adjuvant-related syndrome]. Rev. Neurol. 159(2), 162–164 (2003).
   PubMedGoogle Scholar
• Bonnefont-Rousselot D, Chantalat-Auger C, Teixeira A, Jaudon MC, Pelletier S, Cherin P. Blood oxidative stress status in patients with macrophagic myofasciitis. Biomed. Pharmacother. 58(9), 516–519 (2004).
   PubMed Web of Science ®Google Scholar
• Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56(3), 303–308 (1999).
   PubMed Web of Science ®Google Scholar
• Petersen RC. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256(3), 183–194 (2004).
   PubMed Web of Science ®Google Scholar
• Dickerson BC, Wolk DA. Dysexecutive versus amnesic phenotypes of very mild Alzheimer’s disease are associated with distinct clinical, genetic and cortical thinning characteristics. J. Neurol. Neurosurg. Psychiatry 82(1), 45–51 (2011).
   PubMed Web of Science ®Google Scholar
• Cadusseau J, Ragunathan-Thangarajah N, Surenaud M, Hue S, Authier FJ, Gherardi RK. Selective elevation of circulating CCL2/MCP1 levels in patients with longstanding post-vaccinal macrophagic myofasciitis and ASIA. Curr. Med. Chem. 21(4), 511–517 (2014).
   PubMed Web of Science ®Google Scholar
• Ganrot PO. Metabolism and possible health effects of aluminum. Environ. Health Perspect. 65, 363–441 (1986).
   PubMed Web of Science ®Google Scholar
• Shin RW, Lee VM, Trojanowski JQ. Aluminum modifies the properties of Alzheimer’s disease PHF tau proteins in vivo and in vitro. J. Neurosci. 14(11 Pt 2), 7221–7233 (1994).
   PubMed Web of Science ®Google Scholar
• Redhead K, Quinlan GJ, Das RG, Gutteridge JM. Aluminium-adjuvanted vaccines transiently increase aluminium levels in murine brain tissue. Pharmacol. Toxicol. 70(4), 278–280 (1992).
   PubMedGoogle Scholar
• Petrik MS, Wong MC, Tabata RC, Garry RF, Shaw CA. Aluminum adjuvant linked to Gulf War illness induces motor neuron death in mice. Neuromol. Med. 9(1), 83–100 (2007).
   PubMed Web of Science ®Google Scholar
• Lujan L, Perez M, Salazar E et al. Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA syndrome) in commercial sheep. Immunol. Res. 56(2–3), 317–324 (2013).
   PubMed Web of Science ®Google Scholar
• Corrigan FM, Reynolds GP, Ward NI. Hippocampal tin, aluminum and zinc in Alzheimer’s disease. Biometals 6(3), 149–154 (1993).
   PubMed Web of Science ®Google Scholar
• Dietert RR, Dietert JM. Potential for early-life immune insult including developmental immunotoxicity in autism and autism spectrum disorders: focus on critical windows of immune vulnerability. J. Toxicol. Environ. Health B Crit. Rev. 11(8), 660–680 (2008).
   PubMed Web of Science ®Google Scholar
• Poole RL, Hintz SR, Mackenzie NI, Kerner JA Jr. Aluminum exposure from pediatric parenteral nutrition: meeting the new FDA regulation. JPEN J. Parenter. Enteral. Nutr. 32(3), 242–246 (2008).
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y, Agmon-Levin N. ‘ASIA’ – autoimmune/inflammatory syndrome induced by adjuvants. J. Autoimmun. 36(1), 4–8 (2011).
   PubMed Web of Science ®Google Scholar
• Agmon-Levin N, Hughes G, Shoenfeld Y. The spectrum of ASIA: ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’. Lupus 21(2), 118–120 (2012).
   PubMed Web of Science ®Google Scholar
• Rosenblum H, Shoenfeld Y, Amital H. The common immunogenic etiology of chronic fatigue syndrome: from infections to vaccines via adjuvants to the ASIA syndrome. Infect. Dis. Clin. N. Am. 25, 851–863 (2011).
   PubMed Web of Science ®Google Scholar
• Meroni PL. Autoimmune or auto-inflammatory syndrome induced by adjuvants (ASIA): old truths and a new syndrome? J. Autoimmun. 36(1), 1–3 (2010).
   PubMed Web of Science ®Google Scholar
• Quiroz-Rothe E, Ginel PJ, Pérez J, Lucena R, Rivero JLL. Vaccine-associated acute polyneuropathy resembling Guillain-Barré syndrome in a dog. Eur. J. Companion Animal Practice 15(2), 155 (2005).
   Google Scholar
• Hogenesch H, Azcona-Olivera J, Scott-Moncrieff C, Snyder PW, Glickman LT. Vaccine-induced autoimmunity in the dog. Adv. Vet. Med. 41, 733–747 (1999).
   PubMedGoogle Scholar
• Shoenfeld Y, Aron-Maor A. Vaccination and autoimmunity-’vaccinosis’: a dangerous liaison? J. Autoimmun. 14(1), 1–10 (2000).
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC, Colegio OR, O’Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 453(7198), 1122–1126 (2008).
   PubMed Web of Science ®Google Scholar
• Li H, Nookala S, Re F. Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J. Immunol. 178(8), 5271–5276 (2007).
   PubMed Web of Science ®Google Scholar
• Exley C, Siesjo P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. 31(3), 103–109 (2010).
   PubMed Web of Science ®Google Scholar
• Jha S, Srivastava SY, Brickey WJ et al. The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J. Neurosci. 30(47), 15811–15820 (2010).
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Kaushik DK, Gupta M, Basu A. Inflammasome signaling at the heart of central nervous system pathology. J. Neurosci. Res. 88(8), 1615–1631 (2010).
   PubMed Web of Science ®Google Scholar
• Rajamaki K, Lappalainen J, Oorni K et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS ONE 5(7), e11765 (2010).
   PubMed Web of Science ®Google Scholar
• Wen H, Gris D, Lei Y et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat. Immunol. 12(5), 408–415 (2011).
   PubMed Web of Science ®Google Scholar
• Bauer C, Duewell P, Mayer C et al. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59(9), 1192–1199 (2010).
   PubMed Web of Science ®Google Scholar
• Exley C, Mamutse G, Korchazhkina O et al. Elevated urinary excretion of aluminium and iron in multiple sclerosis. Mult. Scler. 12(5), 533–540 (2006).
   PubMed Web of Science ®Google Scholar
• Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 7(3), e33536 (2012).
   PubMed Web of Science ®Google Scholar
• Partinen M, Saarenpaa-Heikkila O, Ilveskoski I et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 7(3), e33723 (2012).
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Arnulf I, Lecendreux M et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 136(Pt 8), 2486–2496 (2013).
   PubMed Web of Science ®Google Scholar
• Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 80(14), 1315–1321 (2013).
   PubMed Web of Science ®Google Scholar
• Miller E, Andrews N, Stellitano L et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 346, f794 (2013).
   PubMed Web of Science ®Google Scholar
• Chen L, Zhang B, Toborek M. Autophagy is involved in nanoalumina-induced cerebrovascular toxicity. Nanomedicine 9(2), 212–221 (2013).
   PubMed Web of Science ®Google Scholar
• Walton JR. An aluminum-based rat model for Alzheimer’s disease exhibits oxidative damage, inhibition of PP2A activity, hyperphosphorylated tau, and granulovacuolar degeneration. J. Inorg. Biochem. 101(9), 1275–1284 (2007).
   PubMed Web of Science ®Google Scholar
• Joshi JG. Aluminum, a neurotoxin which affects diverse metabolic reactions. Biofactors 2(3), 163–169 (1990).
   PubMedGoogle Scholar
• Exley C, Swarbrick L, Gherardi RK, Authier FJ. A role for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med. Hypotheses 72(2), 135–139 (2009).
   PubMed Web of Science ®Google Scholar
• Hindsen M. Contact allergy to aluminium in patients hyposensitized with aluminium-containing hyposensitizing extracts. Contact Dermatitis 53(5), 301–302 (2005).
   PubMed Web of Science ®Google Scholar
• Bergfors E, Trollfors B, Inerot A. Unexpectedly high incidence of persistent itching nodules and delayed hypersensitivity to aluminium in children after the use of adsorbed vaccines from a single manufacturer. Vaccine 22(1), 64–69 (2003).
   PubMed Web of Science ®Google Scholar
• Exley C, Birchall JD. The cellular toxicity of aluminium. J. Theor. Biol. 159(1), 83–98 (1992).
   PubMed Web of Science ®Google Scholar
• Berin MC, Mayer L. Immunophysiology of experimental food allergy. Mucosal Immunol. 2(1), 24–32 (2009).
   PubMed Web of Science ®Google Scholar
• Brandt EB, Strait RT, Hershko D et al. Mast cells are required for experimental oral allergen-induced diarrhea. J. Clin. Invest. 112(11), 1666–1677 (2003).
   PubMed Web of Science ®Google Scholar
• Theoharides TC, Kempuraj D, Redwood L. Autism: an emerging ‘neuroimmune disorder’ in search of therapy. Expert Opin. Pharmacother. 10(13), 2127–2143 (2009).
   PubMed Web of Science ®Google Scholar